Dr. Reddy’s announces new R&D Chief

Hyderabad, April 30, 2007: Dr. Reddy’s today announced Dr. Rajinder Kumar joining the company as its President– Research, Development & Commercialization. This appointment follows from the strategic direction of the company on its journey towards building a strong innovation-led business. Dr. Kumar will lead and integrate Discovery Research, Global Drug Development and Commercialization efforts, including differentiated products. G V Prasad, Vice Chairman & CEO, Dr. Reddy’s said “Dr. Kumar joins us at an exciting time. He brings in rich experience and the necessary management bandwidth to consolidate our new Chemical Entity (NCE) Research and drug development efforts. His expertise will help us accelerate our efforts to build a global innovation-led business.”

Dr. Kumar graduated in Medicine and Surgery from the University of Dundee, UK and is an alumnus of acclaimed institutions like the University of London and University of Birmingham. He is a member of several scientific and clinical organizations and is a Fellow of the Royal Society of Medicine and Member of the Institute of Directors, U.K.

After a distinguished academic and clinical career, Dr. Kumar spent a large part of his career at SmithKline Beecham and Glaxo SmithKline where he held key executive positions of Vice President and Director - Neuroscience and GI, Smith Kline Beecham, USA; Vice President & Global Head of Psychiatry, Clinical Development and Medical Affairs, Glaxo SmithKline. He has also been the President, Research and Development, Ranbaxy Laboratories, India. Dr. Kumar and his team were responsible for the development and implementation of the strategy for experimental medicines and life cycle management, leading to products of differentiated value with significant commercial impact.

Disclaimer
This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy’s
Established in 1984, Dr. Reddy's Laboratories (NYSE: RDY) is an emerging global pharmaceutical company with proven research capabilities. The Company is vertically integrated with a presence across the pharmaceutical value chain. It produces finished dosage forms, active pharmaceutical ingredients and biopharmaceuticals and markets them globally, with focus on India, US, Europe and Russia. The Company conducts research in the areas of diabetes, cardiovascular, anti-infectives, inflammation and cancer.

Contact Information

Investors and Financial Analysts:
Nikhil Shah at nikhilshah@drreddys.com or on +91-40-66511532

Media:
M Mythili at mythilim@drreddys.com or on +91-40-66511620.